|

Epsolay™ (Microencapsulated Benzoyl Peroxide 5%) Cream for the Topical Treatment of Rosacea.

Abramovits, William; Jessu, Rishita; Vincent, Kimberly D; Gupta, Aditya K.

Skinmed ; 21(2): 110-111, 2023.

Article En | MEDLINE | ID: mdl-37158351

EpsolayTM cream is a novel topical treatment that utilizes microencapsulated benzoyl peroxide to treat moderate to severe papulopustular rosacea. It is effective at decreasing, and for some patients clearing, the papules, pustules, and telangiectasias associated with rosacea. It is well-tolerated with minimal adverse effects and has demonstrated efficacy comparable to other topical agents that are used for the condition.

Dermatologic Agents , Rosacea , Humans , Metronidazole , Rosacea/drug therapy , Benzoyl Peroxide/therapeutic use , Administration, Topical , Emollients/therapeutic use , Treatment Outcome

DUOBRII™ (Halobetasol Propionate and Tazarotene) Lotion for Topical Use: A Newly Approved Combination Corticosteroid and Retinoid Topical Treatment of Plaque Psoriasis in Adults.

Gupta, Aditya K; Love, Robin P; Abramovits, William; Vincent, Kimberly D.

Skinmed ; 17(3): 181-183, 2019.

Article En | MEDLINE | ID: mdl-31496472

Adrenal Cortex Hormones/administration & dosage , Clobetasol/analogs & derivatives , Nicotinic Acids/administration & dosage , Psoriasis/drug therapy , Retinoids/administration & dosage , Administration, Topical , Adult , Clobetasol/administration & dosage , Drug Combinations , Humans , Randomized Controlled Trials as Topic , Skin Cream , Treatment Outcome

Dupixent® (Dupilumab): A Newly Approved Interleukin-4 Receptor Antagonist for the Treatment of Atopic Dermatitis in Pediatric Patients.

Gupta, Aditya K; Love, Robin P; Abramovits, William; Vincent, Kimberly D.

Skinmed ; 17(2): 107-109, 2019.

Article En | MEDLINE | ID: mdl-31145061

Antibodies, Monoclonal, Humanized/therapeutic use , Dermatitis, Atopic/drug therapy , Dermatologic Agents/therapeutic use , Adolescent , Antibodies, Monoclonal, Humanized/adverse effects , Child , Child, Preschool , Dermatologic Agents/adverse effects , Humans , Infant , Interleukin-4 Receptor alpha Subunit/antagonists & inhibitors

Ilumya® (Tildrakizumab): A Newly Approved Interluekin-23 Antagonist for the Treatment of Plaque Psoriasis.

Gupta, Aditya K; Versteeg, Sarah G; Abramovits, William; Vincent, Kimberly D.

Skinmed ; 16(5): 321-324, 2018.

Article En | MEDLINE | ID: mdl-30413226

Antibodies, Monoclonal/therapeutic use , Interleukin-23/antagonists & inhibitors , Psoriasis/drug therapy , Antibodies, Monoclonal, Humanized , Humans

Bavencio^® (Avelumab)-A Newly Approved Anti-PD-L1 IgG1 Antibody.

Gupta, Aditya K; Versteeg, Sarah G; Abramovits, William; Vincent, Kimberly D.

Skinmed ; 16(3): 183-187, 2018.

Article En | MEDLINE | ID: mdl-29989538

Antibodies, Monoclonal/pharmacology , Antibodies, Monoclonal/therapeutic use , Antibodies, Monoclonal, Humanized , Humans

Brodalumab (Siliq^®): A Treatment for Plaque Psoriasis.

Gupta, Aditya K; Versteeg, Sarah Versteeg; Abramovits, William; Vincent, Kimberly D.

Skinmed ; 15(4): 281-285, 2017.

Article En | MEDLINE | ID: mdl-28859739

Antibodies, Monoclonal/therapeutic use , Dermatologic Agents/therapeutic use , Psoriasis/drug therapy , Antibodies, Monoclonal/pharmacology , Antibodies, Monoclonal, Humanized , Clinical Trials, Phase I as Topic , Clinical Trials, Phase II as Topic , Clinical Trials, Phase III as Topic , Dermatologic Agents/pharmacology , Humans

MIRVASO (brimonidine tartrate) topical gel 0.33%.

Abramovits, William; Prato, Ana; Vincent, Kimberly D; Scheinfeld, Noah; Gupta, Aditya K.

Skinmed ; 12(1): 41-3, 2014.

Article En | MEDLINE | ID: mdl-24720083

Dermatologic Agents/therapeutic use , Quinoxalines/therapeutic use , Rosacea/drug therapy , Administration, Cutaneous , Adrenergic alpha-2 Receptor Agonists/administration & dosage , Adrenergic alpha-2 Receptor Agonists/therapeutic use , Brimonidine Tartrate , Clinical Trials as Topic , Dermatologic Agents/administration & dosage , Dermatologic Agents/adverse effects , Gels , Humans , Quinoxalines/administration & dosage , Quinoxalines/adverse effects , Rosacea/pathology

PICATO (ingenol mebutate 0.015% and 0.05% gels): a novel treatment for actinic keratosis.

Abramovits, William; Oquendo, Marcial; Vincent, Kimberly D; Gupta, Aditya K.

Skinmed ; 11(2): 111-5, 2013.

Article En | MEDLINE | ID: mdl-23745230

Dermatologic Agents/therapeutic use , Diterpenes/therapeutic use , Keratosis, Actinic/drug therapy , Administration, Cutaneous , Animals , Carcinoma, Squamous Cell/prevention & control , Clinical Trials as Topic , Dermatologic Agents/administration & dosage , Dermatologic Agents/adverse effects , Diterpenes/administration & dosage , Diterpenes/adverse effects , Dose-Response Relationship, Drug , Drug Approval , Gels , Humans , Keratosis, Actinic/complications , Keratosis, Actinic/pathology , Skin Neoplasms/prevention & control , United States , United States Food and Drug Administration